Company News: Celgene and Abraxis BioScience
New Jersey-based biotech Celgene announced an agreement to purchase Abraxis BioScience, a biotech focused on cancer treatments, for $2.9 billion.
Your Email Address: *
Recipient(s) Email Address: *
(Separate multiple e-mail addresses with commas. Limited to 20 addresses.)
The e-mail address(es) that you supply to use this service will only be used to send the requested article.